Conmed (CNMD) Tops Q2 EPS by 1c; Raises Outlook

Go back to Conmed (CNMD) Tops Q2 EPS by 1c; Raises Outlook

CONMED (CNMD) PT Raised to $83 at Needham & Company

August 2, 2018 6:43 AM EDT

Needham & Company raised its price target on CONMED (NASDAQ: CNMD) to $83.00 (from $73.00) while maintaining a Buy rating.

Analyst Mike Matson commented, "CNMD's 2Q18 revenue and EPS beat consensus and management raised its 2018 revenue and maintained its EPS guidance. Revenue growth improved... More